Search

EHA-SWG Scientific Meeting on Red Cell and Iron Metabolism Defects: From Basic Science to Clinical Case Application

Dates: October 12-14, 2023
Location: Budapest, Hungary
Chairs: A Taher & A Iolascon
Collaborating SWG: EHA Specialized Working Group on Red Cells and Iron

 Registration is closed

RegistrationRegistration is closed. Visit this page for more information.

Read more

Meeting program

Saturday, November 4*All times are in EET.

Read more

Highlights of Past EHA (HOPE) Latin America (LA) 2023 - report

October 26, 2023 – São Paulo, Brazil

Meeting chairs:

A Almeida - President EHA

JF Comenalli Marques Jr - President ABHH

C Chiattone - President HEMO 2023

This year, the HOPE LA meeting was held in collaboration with the Associação Brasileira de Hematologia Hemoterapia e…

Read more

EHA Pediatric Hemato-Oncology Course programme

April 10, 202414:00–17:30: Red Cell and ConsultativeWelcome and presentation of the course.  Aims, expectations, and a brief look back. Presenters and topics
M. de Montalembert: Difficult management problems in sickle cell disease
M. D.

Read more

Publications

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.

Read more

SWG Educational Activities

SWG meeting, EHA2023 CongressGuidelines SessionSession title‘The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children.

Read more

The root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.

Read more

‘Rare Cancers in all EU policies’: Prof Elizabeth Macintyre expresses strong EHA support for the Rare Cancers Europe agenda

On September 28, EHA President Elizabeth Macintyre addressed an audience that included Members of the European Parliament, and officials of the European Commission and the European Medicines Agency, as well as members of the Rare Cancers Europe (RCE) partnership.

Read more